OmniAb
OABI1.9600.51% ( -0.010 )
OmniAb (OABI)
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the d...
- Open
- 1.980
- High
- 2.000
- Low
- 1.920
- Prev. Close
- 1.970
- Volume
- 164.78K
- Turnover
- 322.87K
- Avg Price
- 1.959
- Bid/Ask Ratio
- --
- Amplitude
- 4.06%
- 52wk High
- 2.790
- Volume Ratio
- 0.58
- Turnover Ratio
- 0.14%
OmniAb Analyst Rating
View MoreForecast & Rating
May 21, 2026Price forecast
$7.33272.25%
Forecast & RatingStrong buy
7analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 03:17 PM
Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone
- Unusual Whales · 2 days ago, 06:02 AM
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
- PUBT · Jul 16 at 07:00 AM
OmniAb schedules Q2 2026 earnings release and conference call
- PUBT · Jul 13 at 07:08 AM
OmniAb files initial beneficial ownership statement for COO Amechi Ekeke Nwachuku
- PUBT · Jul 13 at 07:03 AM
OmniAb names Amechi Nwachuku as COO
- Simplywall · Jun 30 at 06:51 AM
We're Not Very Worried About OmniAb's (NASDAQ:OABI) Cash Burn Rate
